Bram Ramaekers
0000-0001-5785-9228
Maastricht University Medical Center
10 papers found
Refreshing results…
Early Cost Effectiveness of Whole-Genome Sequencing as a Clinical Diagnostic Test for Patients with Inoperable Stage IIIB,C/IV Non-squamous Non-small-Cell Lung Cancer
Variability of cost trajectories over the last year of life in patients with advanced breast cancer in the Netherlands
R and Shiny for Cost-Effectiveness Analyses: Why and When? A Hypothetical Case Study
Health-related quality of life after prophylactic cranial irradiation for stage III non-small cell lung cancer patients: Results from the NVALT-11/DLCRG-02 phase III study
Arsenic Trioxide for Treating Acute Promyelocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
Clinically inappropriate post hoc exclusion of study participants from test accuracy calculations: the ROMA score, an example from a recent NICE diagnostic assessment
Ixekizumab for Treating Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
Trifluridine–Tipiracil for Previously Treated Metastatic Colorectal Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
Research Costs Investigated: A Study Into the Budgets of Dutch Publicly Funded Drug-Related Research
Response to Letter to the Editor Regarding “Abiraterone Acetate for the Treatment of Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal”
Missing publications? Search for publications with a matching author name.